S&CO Inc. Trims Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

S&CO Inc. decreased its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 17.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,000 shares of the company’s stock after selling 25,000 shares during the quarter. S&CO Inc.’s holdings in Elanco Animal Health were worth $1,453,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ELAN. JPMorgan Chase & Co. raised its position in Elanco Animal Health by 76.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock valued at $147,747,000 after purchasing an additional 4,361,799 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Elanco Animal Health in the 3rd quarter valued at $19,708,000. Private Management Group Inc. increased its stake in Elanco Animal Health by 63.4% in the 4th quarter. Private Management Group Inc. now owns 2,357,142 shares of the company’s stock valued at $28,545,000 after buying an additional 914,808 shares during the period. Raymond James Financial Inc. acquired a new position in Elanco Animal Health in the 4th quarter valued at $10,561,000. Finally, Point72 DIFC Ltd acquired a new position in Elanco Animal Health in the 3rd quarter valued at $9,969,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $10.83 on Tuesday. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a fifty-two week low of $10.20 and a fifty-two week high of $18.80. The stock has a market cap of $5.35 billion, a PE ratio of 27.06, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The firm’s fifty day simple moving average is $11.60 and its 200-day simple moving average is $12.86.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the prior year, the firm earned $0.08 earnings per share. Elanco Animal Health’s quarterly revenue was down 1.4% on a year-over-year basis. Analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ELAN has been the topic of several recent research reports. Barclays dropped their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Finally, Leerink Partners started coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.